Genetic engineering with T cell receptors

Advanced Drug Delivery Reviews

Volumn 64, Issue 8, 2012, Pages 756-762

  Zhang, Ling ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer immunotherapy; Gene therapy; T cell receptor

Indexed keywords

CANCER IMMUNOTHERAPY; CLINICAL EVALUATION; CLINICAL STUDY; GENE TRANSFER SYSTEMS; HUMAN LYMPHOCYTES; IN-VIVO; LABORATORY TECHNOLOGIES; METASTATIC MELANOMA; PROTEIN MODIFICATIONS; T CELL RECEPTOR; T CELLS; T-CELL RECEPTORS; THERAPEUTIC APPLICATION; THERAPEUTIC STRATEGY; TRANSFER PROTOCOL; TUMOR ANTIGEN; TUMOR REGRESSION;

ANTIGENS; CELL MEMBRANES; CYTOLOGY; DISEASES; GENE EXPRESSION; GENE TRANSFER; TUMORS;

GENE THERAPY;

CANCER TESTIS ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DEATH RECEPTOR 4; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; INTERLEUKIN 2; IPILIMUMAB; LENTIVIRUS VECTOR; MELAN A; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; PROTEIN P53; RECOMBINANT INTERLEUKIN 12; RETROVIRUS VECTOR; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; COLORECTAL CANCER; COMPLEMENTARITY DETERMINING REGION; CYTOKINE RELEASE; ELECTROPORATION; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; LYMPHOCYTE DEPLETION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSPOSON; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 84860611911     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.11.009     Document Type: Review

References (73)

1. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
2. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8:299-308.
3. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
4. Blattman J.N., Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 2004, 305:200-205.
5. Romero P., Cerottini J.C., Speiser D.E. The human T cell response to melanoma antigens. Adv. Immunol. 2006, 92:187-224.
6. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005, 5:615-625.
7. Suri A. Cancer testis antigens-their importance in immunotherapy and in the early detection of cancer. Expert. Opin. Biol. Ther. 2006, 6:379-389.
8. Clay T.M., Custer M.C., Sachs J., Hwu P., Rosenberg S.A., Nishimura M.I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 1999, 163:507-513.
9. Morgan R.A., Dudley M.E., Yu Y.Y., Zheng Z., Robbins P.F., Theoret M.R., Wunderlich J.R., Hughes M.S., Restifo N.P., Rosenberg S.A. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 2003, 171:3287-3295.
10. Schaft N., Willemsen R.A., de Vries J., Lankiewicz B., Essers B.W., Gratama J.W., Figdor C.G., Bolhuis R.L., Debets R., Adema G.J. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J. Immunol. 2003, 170:2186-2194.
11. Zhao Y., Zheng Z., Robbins P.F., Khong H.T., Rosenberg S.A., Morgan R.A. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 2005, 174:4415-4423.
12. Chinnasamy N., Wargo J.A., Yu Z., Rao M., Frankel T.L., Riley J.P., Hong J.J., Parkhurst M.R., Feldman S.A., Schrump D.S., Restifo N.P., Robbins P.F., Rosenberg S.A., Morgan R.A. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 2011, 186:685-696.
13. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., Lee C.C., Restifo N.P., Schwarz S.L., Cogdill A.P., Bishop R.J., Kim H., Brewer C.C., Rudy S.F., VanWaes C., Davis J.L., Mathur A., Ripley R.T., Nathan D.A., Laurencot C.M., Rosenberg S.A. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
14. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
15. Cohen C.J., Zhao Y., Zheng Z., Rosenberg S.A., Morgan R.A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006, 66:8878-8886.
16. Cohen C.J., Li Y.F., El-Gamil M., Robbins P.F., Rosenberg S.A., Morgan R.A. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007, 67:3898-3903.
17. Voss R.H., Willemsen R.A., Kuball J., Grabowski M., Engel R., Intan R.S., Guillaume P., Romero P., Huber C., Theobald M. Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J. Immunol. 2008, 180:391-401.
18. Okamoto S., Mineno J., Ikeda H., Fujiwara H., Yasukawa M., Shiku H., Kato I. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009, 69:9003-9011.
19. Robbins P.F., Li Y.F., El-Gamil M., Zhao Y., Wargo J.A., Zheng Z., Xu H., Morgan R.A., Feldman S.A., Johnson L.A., Bennett A.D., Dunn S.M., Mahon T.M., Jakobsen B.K., Rosenberg S.A. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 2008, 180:6116-6131.
20. Parkhurst M.R., Joo J., Riley J.P., Yu Z., Li Y., Robbins P.F., Rosenberg S.A. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res. 2009, 15:169-180.
21. Wang Q.J., Hanada K., Feldman S.A., Zhao Y., Inozume T., Yang J.C. Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. J. Immunol. Methods 2011, 366:43-51.
22. Kuball J., Hauptrock B., Malina V., Antunes E., Voss R.H., Wolfl M., Strong R., Theobald M., Greenberg P.D. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J. Exp. Med. 2009, 206:463-475.
23. Scholten K.B., Kramer D., Kueter E.W., Graf M., Schoedl T., Meijer C.J., Schreurs M.W., Hooijberg E. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 2006, 119:135-145.
24. Cohen C.J., Zheng Z., Bray R., Zhao Y., Sherman L.A., Rosenberg S.A., Morgan R.A. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 2005, 175:5799-5808.
25. Davis J.L., Theoret M.R., Zheng Z., Lamers C.H., Rosenberg S.A., Morgan R.A. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 2010, 16:5852-5861.
26. Zhao Y., Bennett A.D., Zheng Z., Wang Q.J., Robbins P.F., Yu L.Y., Li Y., Molloy P.E., Dunn S.M., Jakobsen B.K., Rosenberg S.A., Morgan R.A. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 2007, 179:5845-5854.
27. Riviere I., Brose K., Mulligan R.C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:6733-6737.
28. Schambach A., Swaney W.P., van der Loo J.C. Design and production of retro- and lentiviral vectors for gene expression in hematopoietic cells. Methods Mol. Biol. 2009, 506:191-205.
29. Hughes M.S., Yu Y.Y., Dudley M.E., Zheng Z., Robbins P.F., Li Y., Wunderlich J., Hawley R.G., Moayeri M., Rosenberg S.A., Morgan R.A. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 2005, 16:457-472.
30. Yang S., Cohen C.J., Peng P.D., Zhao Y., Cassard L., Yu Z., Zheng Z., Jones S., Restifo N.P., Rosenberg S.A., Morgan R.A. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 2008, 15:1411-1423.
31. Yang S., Rosenberg S.A., Morgan R.A. Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J. Immunother. 2008, 31:830-839.
32. Wu X., Li Y., Crise B., Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300:1749-1751.
33. Singh H., Manuri P.R., Olivares S., Dara N., Dawson M.J., Huls H., Hackett P.B., Kohn D.B., Shpall E.J., Champlin R.E., Cooper L.J. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008, 68:2961-2971.
34. Hackett P.B., Largaespada D.A., Cooper L.J. A transposon and transposase system for human application. Mol. Ther. 2010, 18:674-683.
35. Nakazawa Y., Huye L.E., Salsman V.S., Leen A.M., Ahmed N., Rollins L., Dotti G., Gottschalk S.M., Wilson M.H., Rooney C.M. PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor. Mol. Ther. 2011, 12:2133-2143.
36. Zhao Y., Zheng Z., Cohen C.J., Gattinoni L., Palmer D.C., Restifo N.P., Rosenberg S.A., Morgan R.A. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 2006, 13:151-159.
37. Zhao Y., Moon E., Carpenito C., Paulos C.M., Liu X., Brennan A.L., Chew A., Carroll R.G., Scholler J., Levine B.L., Albelda S.M., June C.H. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010, 70:9053-9061.
38. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., Davis J.L., Morgan R.A., Merino M.J., Sherry R.M., Hughes M.S., Kammula U.S., Phan G.Q., Lim R.M., Wank S.A., Restifo N.P., Robbins P.F., Laurencot C.M., Rosenberg S.A. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 2011, 19:620-626.
39. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., Kammula U.S., Hughes M.S., Restifo N.P., Raffeld M., Lee C.C., Levy C.L., Li Y.F., El-Gamil M., Schwarz S.L., Laurencot C., Rosenberg S.A. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29:917-924.
40. Rosenberg S.A., Sherry R.M., Morton K.E., Scharfman W.J., Yang J.C., Topalian S.L., Royal R.E., Kammula U., Restifo N.P., Hughes M.S., Schwartzentruber D., Berman D.M., Schwarz S.L., Ngo L.T., Mavroukakis S.A., White D.E., Steinberg S.M. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 2005, 175:6169-6176.
41. O'Garra A., Barrat F.J., Castro A.G., Vicari A., Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 2008, 223:114-131.
42. Flavell R.A., Sanjabi S., Wrzesinski S.H., Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 2010, 10:554-567.
43. Filippi C.M., Juedes A.E., Oldham J.E., Ling E., Togher L., Peng Y., Flavell R.A., von Herrath M.G. Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes 2008, 57:2684-2692.
44. Gorelik L., Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 2001, 7:1118-1122.
45. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007, 67:425. author reply 426.
46. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 2007, 25:2546-2553.
47. Nagaraj S., Gabrilovich D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008, 68:2561-2563.
48. Nagaraj S., Gabrilovich D.I. Myeloid-derived suppressor cells in human cancer. Cancer J. 2010, 16:348-353.
49. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., Rosenberg S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
50. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
51. Sarnaik A.A., Weber J.S. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J. 2009, 15:169-173.
52. Wing K., Yamaguchi T., Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol. 2011, 9:428-433.
53. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., Baker J., Jeffery L.E., Kaur S., Briggs Z., Hou T.Z., Futter C.E., Anderson G., Walker L.S., Sansom D.M. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
54. Gattinoni L., Finkelstein S.E., Klebanoff C.A., Antony P.A., Palmer D.C., Spiess P.J., Hwang L.N., Yu Z., Wrzesinski C., Heimann D.M., Surh C.D., Rosenberg S.A., Restifo N.P. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907-912.
55. Borkner L., Kaiser A., van de Kasteele W., Andreesen R., Mackensen A., Haanen J.B., Schumacher T.N., Blank C. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol. Immunother. 2010, 59:1173-1183.
56. Bishop K.D., Harris J.E., Mordes J.P., Greiner D.L., Rossini A.A., Czech M.P., Phillips N.E. Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism. Cell. Immunol. 2009, 256:86-91.
57. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
58. Charo J., Finkelstein S.E., Grewal N., Restifo N.P., Robbins P.F., Rosenberg S.A. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 2005, 65:2001-2008.
59. Kalbasi A., Shrimali R.K., Chinnasamy D., Rosenberg S.A. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J. Immunother. 2010, 33:672-683.
60. Hu Z., Gerseny H., Zhang Z., Chen Y.J., Berg A., Stock S., Seth P. Oncolytic Adenovirus Expressing Soluble TGFbeta Receptor II-Fc-mediated Inhibition of Established Bone Metastases: A Safe and Effective Systemic Therapeutic Approach for Breast Cancer. Mol. Ther. 2011, 9:1609-1618.
61. Yang Y.A., Dukhanina O., Tang B., Mamura M., Letterio J.J., MacGregor J., Patel S.C., Khozin S., Liu Z.Y., Green J., Anver M.R., Merlino G., Wakefield L.M. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 2002, 109:1607-1615.
62. Lacuesta K., Buza E., Hauser H., Granville L., Pule M., Corboy G., Finegold M., Weiss H., Chen S.Y., Brenner M.K., Heslop H.E., Rooney C.M., Bollard C.M. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J. Immunother. 2006, 29:250-260.
63. Gately M.K. Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. Cancer Invest. 1993, 11:500-506.
64. Mehrotra P.T., Wu D., Crim J.A., Mostowski H.S., Siegel J.P. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J. Immunol. 1993, 151:2444-2452.
65. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.P., Maggi E., Trinchieri G., Romagnani S. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 1993, 177:1199-1204.
66. Kennedy M.K., Picha K.S., Shanebeck K.D., Anderson D.M., Grabstein K.H. Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur. J. Immunol. 1994, 24:2271-2278.
67. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., Wolf S.F., Gately M.K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 1993, 178:1223-1230.
68. Tahara H., Zitvogel L., Storkus W.J., Robbins P.D., Lotze M.T. Murine models of cancer cytokine gene therapy using interleukin-12. Ann. N. Y. Acad. Sci. 1996, 795:275-283.
69. Colombo M.P., Vagliani M., Spreafico F., Parenza M., Chiodoni C., Melani C., Stoppacciaro A. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 1996, 56:2531-2534.
70. Cavallo F., Di Carlo E., Butera M., Verrua R., Colombo M.P., Musiani P., Forni G. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res. 1999, 59:414-421.
71. Kerkar S.P., Muranski P., Kaiser A., Boni A., Sanchez-Perez L., Yu Z., Palmer D.C., Reger R.N., Borman Z.A., Zhang L., Morgan R.A., Gattinoni L., Rosenberg S.A., Trinchieri G., Restifo N.P. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010, 70:6725-6734.
72. Zhang L., Kerkar S.P., Yu Z., Zheng Z., Yang S., Restifo N.P., Rosenberg S.A., Morgan R.A. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 2011, 19:751-759.
73. Butler M.O., Friedlander P., Milstein M.I., Mooney M.M., Metzler G., Murray A.P., Tanaka M., Berezovskaya A., Imataki O., Drury L., Brennan L., Flavin M., Neuberg D., Stevenson K., Lawrence D., Hodi F.S., Velazquez E.F., Jaklitsch M.T., Russell S.E., Mihm M., Nadler L.M., Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci. Transl. Med. 2011, 3:80ra34.